The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Pembrolizumab, bevacizumab & CAPOX for pMMR/MSS mCRC in the POCHI trial
Shouki Bazarbashi, MBBS, Alfaisal University & King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, gives an overview of results from the Phase II POCHI trial (NCT04262687), which examined pembrolizumab with CAPOX and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate. The investigational therapy showed promising response rates, and recruitment is ongoing. The findings suggest that this subset of patients with pMMR/MSS mCRC may benefit from immunotherapy. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
